FACP MD - Iteos Therapeutics Interim Officer
| ITOS Stock | USD 7.09 0.27 3.67% |
Executive
FACP MD is Interim Officer of Iteos Therapeutics
| Age | 53 |
| Phone | 339 217 0161 |
| Web | https://www.iteostherapeutics.com |
Iteos Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1447) % which means that it has lost $0.1447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2307) %, meaning that it created substantial loss on money invested by shareholders. Iteos Therapeutics' management efficiency ratios could be used to measure how well Iteos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Terry MD | Sana Biotechnology | 57 | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| MPH MD | Tscan Therapeutics | 48 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Sonja MD | Sana Biotechnology | 50 | |
| Adam JD | Day One Biopharmaceuticals | 58 | |
| Edmund Dunn | Monte Rosa Therapeutics | 59 | |
| JD Esq | Terns Pharmaceuticals | 56 | |
| James Kanter | Terns Pharmaceuticals | N/A | |
| Nicolas Mosimann | MoonLake Immunotherapeutics | N/A | |
| MS CPA | Erasca Inc | 58 | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| JD Esq | Erasca Inc | 53 | |
| Ariel Hurley | Blueprint Medicines Corp | 51 | |
| Camille MD | Amylyx Pharmaceuticals | 72 | |
| Farah Anwar | Sana Biotechnology | N/A | |
| JD Esq | Kymera Therapeutics | 66 | |
Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.14 |
Iteos Therapeutics Leadership Team
Elected by the shareholders, the Iteos Therapeutics' board of directors comprises two types of representatives: Iteos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Iteos. The board's role is to monitor Iteos Therapeutics' management team and ensure that shareholders' interests are well served. Iteos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Iteos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Gall, Chief Officer | ||
| Matthew MBA, Chief Officer | ||
| Ryan Baker, Head Relations | ||
| Phillipe Brantegem, VicePresident Resources | ||
| Joanne MD, Chief Officer | ||
| Adi Osovsky, Executive Legal | ||
| Michel Detheux, CEO President | ||
| Yvonne McGrath, Chief Officer | ||
| FACP MD, Interim Officer | ||
| David MD, Chief Officer | ||
| Philippe Brantegem, Executive Resources |
Iteos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Iteos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.14 | ||||
| Operating Margin | (4.48) % | ||||
| Current Valuation | (208.44 M) | ||||
| Shares Outstanding | 38.19 M | ||||
| Shares Owned By Insiders | 1.10 % | ||||
| Shares Owned By Institutions | 91.18 % | ||||
| Number Of Shares Shorted | 1.58 M | ||||
| Price To Earning | 50.50 X | ||||
| Price To Book | 0.48 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.